跳至主要内容
临床试验/IRCT2017010631252N3
IRCT2017010631252N3已完成3 期

Investigation the effect of adding Atorvastatin to routine Tenofovir treatment on severity of liver fibrosis and liver function among patients with chronic hepatitis B

Qom University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Patients between 18 and 75 years old with chronic hepatitis B for more than 6 months and dysfunction in liver function, serum LDL more than 90 mg/dl
  • Exclusion criteria: Patients with hepatitis B less than 6 months, Inactive carriers of hepatitis B, Patients with no fibrosis and cirrhosis, Patients with decompensated cirrhosis, Patients with chronic liver disease such as willson and hemochromatosis, Patients with hepatic cell carcinoma, Patients with other malignancies, Patients with co-infection and superinfection of HIV ,HCV or HDV, Patients that were treated with Atorvastatin, Pregnant and lactating women, Increasing of liver enzymes 2 times of normal range after 1 months of treatment.

排除标准

  • 未提供

研究者

相似试验